

Amendments to the Claims:

Please amend claim 40 as follows. This listing of claims will replace all prior versions and listings of claims in this application:

Listing of Claims:

1-39. **(Canceled).**

40. **(Currently amended)** An isolated antibody or antigen-binding fragment thereof that specifically binds to pleiotrophin (PTN) comprising any one of the following:

(a) a monoclonal antibody or antigen-binding fragment thereof produced by [[the]] hybridoma cell line 3B10 having ATCC deposit designation PTA-11180;

(b) an antibody or antigen-binding fragment thereof that binds to an epitope, which is the same as an epitope of the monoclonal antibody or antigen-binding fragment thereof produced by [[the]] hybridoma cell line 3B10 having ATCC deposit designation PTA-11180; or

(c) an antibody that competitively inhibits binding of a PTN polypeptide to an antibody comprising: (i) a light chain CDR1 sequence of SEQ ID NO:10, (ii) a light chain CDR2 sequence of SEQ ID NO:11, (iii) a light chain CDR3 sequence of SEQ ID NO:12, (iv) a heavy chain CDR1 sequence of SEQ ID NO:5, (v) a heavy chain CDR2 sequence of SEQ ID NO:6 and (vi) a heavy chain CDR3 sequence of SEQ ID NO:7.

41-45. **(Canceled).**

46. **(Previously presented)** The antibody or antigen-binding fragment thereof according to claim 40, wherein the antibody or antigen-binding fragment comprises: (i) a light chain CDR1 sequence of SEQ ID NO:10, (ii) a light chain CDR2 sequence of SEQ ID NO:11, (iii) a light chain CDR3 sequence of SEQ ID NO:12, (iv) a heavy chain CDR1 sequence of SEQ ID NO:5, (v) a heavy chain CDR2 sequence of SEQ ID NO:6 and (vi) a heavy chain CDR3 sequence of SEQ ID NO:7.

47. **(Previously presented)** The antibody or antigen-binding fragment thereof according to claim 46, wherein said antibody comprises a heavy chain variable domain amino acid sequence comprising SEQ ID NOs: 3 and a light chain variable domain amino acid sequence comprising SEQ ID NOs: 8.

48. **(Canceled).**

49. **(Previously presented)** The antibody or antigen-binding fragment thereof according to claim 40, wherein said antibody is selected from the group consisting of a chimeric antibody, humanized antibody, and a fully human antibody.

50. **(Previously presented)** The antibody or antigen-binding fragment thereof according to claim 40, wherein said antigen-binding fragment is selected from the group consisting of Fab fragment, (Fab')₂ Fragment, and a Fv fragment.

51. **(Previously presented)** The antibody or antigen-binding fragment thereof of claim 40, wherein the antibody is conjugated to a cytotoxic agent.

52. **(Canceled).**

53. **(Previously presented)** The antibody or antigen-binding fragment thereof according to claim 40, wherein said antibody binds to a PTN epitope at a binding affinity of at least $10^6 M^{-1}$.

54. **(Previously presented)** A pharmaceutical composition comprising the antibody according to claim 40 and a pharmaceutical carrier.

55. **(Canceled).**